Simultaneous determination of GTS-21 and its metabolite in rat plasma by high-performance liquid chromatography using solid-phase extraction

J Chromatogr B Biomed Appl. 1996 Nov 15;686(2):229-34. doi: 10.1016/s0378-4347(96)00233-2.


It has been suggested that GTS-21 can improve the learning deficits and inhibit the neuro-degeneration in patients with Alzheimer's disease. This paper describes a reversed-phase high-performance liquid chromatographic assay with visible detection at 405 nm for determination of GTS-21 and its metabolite, 4-hydroxy-GTS-21 in rat plasma. The method uses solid-phase extraction with a Bond Elut C18 column. A quantitation limit of 1.0 ng/ml was achieved using 0.5 ml of rat plasma. In the validation study, the coefficients of variation and the relative errors of each compound were less than 10%. Also freeze-thaw and storage stability were confirmed. This method has proved to be applicable to the pharmacokinetic study of GTS-21 in rats.

MeSH terms

  • Animals
  • Benzylidene Compounds / blood*
  • Benzylidene Compounds / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods*
  • Male
  • Nicotinic Agonists / blood*
  • Nicotinic Agonists / pharmacokinetics
  • Pyridines / blood*
  • Pyridines / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Reproducibility of Results
  • Sensitivity and Specificity


  • Benzylidene Compounds
  • Nicotinic Agonists
  • Pyridines
  • 3-(2,4-dimethoxybenzylidene)anabaseine